Distal gastric cancer complicated with type ? diabetes mellitus
Conditions
Interventions
Group 1:Billroth I anastomosis of distal gastric cancer
Group 2:Billroth II anastomosis of distal gastric cancer
Group 3:Radical resection of distal gastric cancer with Roux-en-Y anastomosis
Sponsors
The First Affiliated Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with initially resectable distal gastric cancer confirmed by gastroscopy and pathology; 2. TxNxM0 patients without distant organ metastasis; 3. During oral glucose tolerance test, 2 h blood glucose >=11.1 mmol/ml; 4. Glycosylated hemoglobin A1c >=6.5%; 5. Fasting blood glucose FPG >=7.0mmol/l. Fasting is defined as no calorie intake for at least 8 hours; 6. Random blood glucose >=11.1 mmol/l in patients with typical hyperglycemia or hyperglycemia crisis symptoms; 7. The history of diabetes mellitus less than 15 years; 8. Been cured and discharged from hospital after operation, and the estimated survival time was more than 6 months. 9. Evaluation of cardiopulmonary function can tolerate anesthesia and surgery; 10. Aged 18-80 years old; 11. The subjects voluntarily joined the study and signed an informed consent form with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Preoperative evaluation of patients who need total gastrectomy or proximal gastrectomy; 2. Patients with distant metastasis or colleagues with other tumors; 3. Preoperative evaluation of cardiopulmonary function can not tolerate anesthesia and surgery; 4. Patients with a history of gastrointestinal surgery; 5. Patients with chronic hepatitis (such as hepatitis B, hepatitis C, autoimmune hepatitis), liver cirrhosis (alcoholic cirrhosis, viral cirrhosis, unexplained cirrhosis), and patients undergoing liver transplantation. 6. Patients with chronic pancreatitis and immune pancreatic disease; 7. Chronic diseases complicated with long-term hormone therapy; 8. Subjects are being treated with immunosuppressants, or systemic or absorbable local hormones for immunosuppressive purposes (dose > 10mg/ prednisone or other therapeutic hormones) and continue to use them within 2 weeks before entering the group; 9. The subjects had acute cardio-cerebrovascular diseases such as acute cerebral infarction and acute coronary syndrome within 3 months, and the cardiovascular clinical symptoms or diseases could not be well controlled; 10. Patients with a history of psychotropic substance abuse and unable to quit or with mental disorders; 11. According to the judgment of the researchers, patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study; 12. The researchers believe that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting glucose;Postprandial blood glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1Y-RFS;1Y-OS;OS;RFS;QoL; | — |
Countries
China
Contacts
Public ContactHu Sanyuan
The First Affiliated Hospital of Shandong First Medical University
Outcome results
None listed